Key Highlights

● Inhibrx Biosciences shares fell 24.0%, among the hardest-hit US stocks.

● No confirmed company-specific catalyst could be established for the drop.

● Declines of this size typically signal a clinical-stage development.

● Major US indexes closed modestly higher on October 28 amid a mixed session.

Inhibrx Biosciences (NASDAQ:INBX) ranked among the hardest-hit US stocks on Wednesday, October 28, 2026, closing the regular session down 24.0%. A decline of that size in a clinical-stage biotechnology name typically signals a company-specific development, but in this case no confirmed catalyst could be established from the session's reconciled sources. In keeping with a disciplined approach, this write-up will not attribute the drop to any particular trial result, regulatory action, financing, or corporate event that cannot be substantiated. What is verifiable is the move itself; the reason behind it is not.

A Steep, Unexplained Decline

The most honest characterization is that the decline looks biotech-specific rather than the product of any broad-market force. Development-stage drug developers concentrate much of their value in a handful of programs, so a single piece of news touching a lead asset can move the shares violently within a session. A roughly one-quarter loss is consistent with that dynamic. Consistency with a familiar pattern, however, is not proof of a specific cause, and without reliable reporting linking Wednesday's slide to an identifiable disclosure, the appropriate conclusion is that the trigger could not be confirmed from the information available for this session.

Session Backdrop

The wider market gives no support to the idea that INBX was swept lower by the overall tape. US equities finished modestly higher on October 28. The S&P 500 rose about 0.3% to close near 7,744, the Nasdaq Composite advanced roughly 0.3%, the Dow Jones Industrial Average gained around 0.2%, and the Russell 2000 added about 0.4%. Leadership came from semiconductors and AI-infrastructure names, with the Philadelphia Semiconductor Index up 1.75% on the day. Against a backdrop of mildly positive indexes and chip-sector strength, a 24% decline in a single biotechnology stock reads as idiosyncratic, disconnected from the forces driving the headline averages.

Breadth beneath the surface was more mixed than the index gains suggest, with decliners leading advancers for much of the morning and six of eleven S&P 500 sectors finishing lower. That texture reflects an exceptionally heavy earnings day that produced sharp moves in individual names in both directions. Even so, neutral-to-mixed breadth does not translate into a 24% loss for any one company; it simply indicates that beneath a quietly higher close there was considerable dispersion. For INBX, the dispersion was unmistakable, but its specific source remained unverified.

The macro environment added a cautious tone that generally bears on cash-consuming, long-duration equities such as pre-revenue biotech, though it cannot explain a move of this magnitude. The Federal Reserve held its policy rate at 3.75%–4.00% in a 10–2 vote, with two officials dissenting in favor of a quarter-point hike, and the statement leaned higher-for-longer, describing activity as expanding at a strong pace with inflation still elevated. The 10-year Treasury yield climbed to roughly 5.03%. Rising yields and a firmer policy signal tend to pressure companies whose value rests on distant cash flows and who may rely on future capital raises. That context is relevant to how clinical-stage biotech trades in aggregate, but it is backdrop rather than a stock-specific explanation.

An Unverified Move Calls for Caution

For anyone trying to understand why INBX fell 24.0% on Wednesday, the responsible answer is that the specific driver was not confirmed from the sources reconciled for this session, even though the severity and profile of the move fit a biotech-specific event. Rather than adopting an inferred storyline, investors would be better served by reviewing the company's own primary disclosures and official filings, which would provide any verified account of the day's developments.